NovoCure (NVCR) Net Income towards Common Stockholders Growth (5y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.71% |
| Dec 31, 2025 | -47.50% |
| Sep 30, 2025 | -43.17% |
| Jun 30, 2025 | -92.24% |
| Mar 31, 2025 | -60.60% |
| Dec 31, 2024 | -77.21% |
| Sep 30, 2024 | -77.94% |
| Jun 30, 2024 | -92.28% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -24.67% |
| Sep 30, 2023 | -33.44% |
| Jun 30, 2023 | -29.92% |
| Mar 31, 2023 | -20.69% |
| Dec 31, 2022 | -27.79% |
| Sep 30, 2022 | -18.24% |
| Jun 30, 2022 | -2.54% |
| Mar 31, 2022 | 23.76% |
| Dec 31, 2021 | -19.63% |
| Sep 30, 2021 | 17.15% |
| Jun 30, 2021 | 18.46% |
| Mar 31, 2021 | 34.95% |
| Dec 31, 2020 | 16.54% |
| Sep 30, 2020 | 18.70% |
| Jun 30, 2020 | 15.51% |
| Mar 31, 2020 | 16.76% |
| Dec 31, 2019 | -34.51% |
| Sep 30, 2019 | 16.06% |